{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T06:22:37Z","timestamp":1725603757258},"publisher-location":"Berlin, Heidelberg","reference-count":34,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"type":"print","value":"9783642624124"},{"type":"electronic","value":"9783642190223"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003]]},"DOI":"10.1007\/978-3-642-19022-3_13","type":"book-chapter","created":{"date-parts":[[2011,8,29]],"date-time":"2011-08-29T09:17:45Z","timestamp":1314609465000},"page":"146-158","source":"Crossref","is-referenced-by-count":1,"title":["Chemosensitivity Testing in Gynecologic Oncology \u2014 Dream or Reality?"],"prefix":"10.1007","author":[{"given":"M.","family":"Untch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Ditsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Langer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Kurbacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Crohns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Konecny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Kahlert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Bauerfeind","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Hepp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"17","key":"13_CR1","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1038\/sj.onc.1202132","volume":"17","author":"RJ Pietras","year":"1998","unstructured":"Pietras RJ, Pegram MD, Finn RS, Maneval DA, Slamon DJ (1998) Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene 17(17):2235\u20132249","journal-title":"Oncogene"},{"key":"13_CR2","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1126\/science.560061","volume":"197","author":"AW Hamburger","year":"1977","unstructured":"Hamburger AW, Salmon SE (1977) Primary bioassay of human tumor stem cells. Science 197:161\u2013163","journal-title":"Science"},{"key":"13_CR3","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1093\/jnci\/82.2.110","volume":"82","author":"SS Hoff Von","year":"1991","unstructured":"Von Hoff SS, Kronmal R, Slamon SE et al. (1991) Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician. J Natl Cancer Inst 82:110\u2013116","journal-title":"J Natl Cancer Inst"},{"key":"13_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/1097-0142(19910101)67:1<20::AID-CNCR2820670105>3.0.CO;2-U","volume":"67","author":"DD Hoff Von","year":"1991","unstructured":"Von Hoff DD, Kronmal R, Salmon SE et al. (1991) A Southwest Oncology Group study on the use of a human tumor cloning assay for predicting response in patients with ovarian cancer. Cancer 67:20\u201327","journal-title":"Cancer"},{"key":"13_CR5","doi-asserted-by":"publisher","first-page":"690","DOI":"10.2165\/00003495-199244050-00002","volume":"44","author":"WT Bellamy","year":"1992","unstructured":"Bellamy WT (1992) Prediction of response to drug therapy of cancer. A review of in vitro assays. Drugs 44:690\u2013708","journal-title":"Drugs"},{"key":"13_CR6","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1200\/JCO.1999.17.5.1625","volume":"17","author":"P Cortazar","year":"1999","unstructured":"Cortazar P, Jonson BE (1999) Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer. J Clin Oncol 17:1625","journal-title":"J Clin Oncol"},{"key":"13_CR7","first-page":"338","volume":"62","author":"L Kangas","year":"1984","unstructured":"Kangas L, Gr\u00f6nroos M, Nieminen A (1984) Bioluminescence of cellular ATP: a new method for evaluating cytotoxic agents in vitro. Med Biol 62:338\u2013343","journal-title":"Med Biol"},{"key":"13_CR8","unstructured":"Sevin et al (1988)"},{"key":"13_CR9","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/BF01807161","volume":"41","author":"CM Kurbacher","year":"1996","unstructured":"Kurbacher CM, Cree IA, Brenne U, Bruckner HW, Kurbacher JA, Mallmann P, Andreotti PE, Krebs D (1996) Heterogeneity of in vitro chemosensitivity in perioperative breast cancer cells to mitoxantrone versus doxorubicin evaluated by a microplate ATP bioluminescence assay. Breast Cancer Res Treat 41:161\u2013170","journal-title":"Breast Cancer Res Treat"},{"key":"13_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1006\/gyno.1994.1085","volume":"54","author":"M Untch","year":"1994","unstructured":"Untch M, Sevin BU, Perras JP, Angioli R, Untch A, Hightower RD, K\u00f6chli OR, Averette HE (1994) Evaluation of Paclitaxel (Taxol), Cisplatin, and the Combination Paclitaxel-Cisplatin in Ovarian Cancer in vitro with the ATP Cell Viability Assay. Gynecol Oncol 54:44\u201349","journal-title":"Gynecol Oncol"},{"key":"13_CR11","first-page":"5276","volume":"55","author":"PE Andreotti","year":"1995","unstructured":"Andreotti PE, Cree IA, Kurbacher CM et al. (1995) Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 55:5276\u20135282","journal-title":"Cancer Res"},{"issue":"suppl 1","key":"13_CR12","first-page":"86","volume":"258","author":"T Ackermann","year":"1996","unstructured":"Ackermann T, Kurbacher CM, Mallmann P et al. (1996) Wachstumscharakteristika von Normalzellen im ATP-Tumor-Chemosensitivit\u00e4ts-Assay. Arch Gynecol Obstet 258 (suppl 1):86","journal-title":"Arch Gynecol Obstet"},{"key":"13_CR13","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1097\/00001813-199608000-00002","volume":"7","author":"IA Cree","year":"1996","unstructured":"Cree IA, Kurbacher CM, Untch M et al. (1996) Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anti-Cancer Drugs 7:630\u2013635","journal-title":"Anti-Cancer Drugs"},{"key":"13_CR14","first-page":"5276","volume":"55","author":"PE Andreotti","year":"1995","unstructured":"Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, Gleiberman I, Caruso PA, Ricks SH, Untch M, et al. (1995) Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 55:5276\u20135282","journal-title":"Cancer Res"},{"key":"13_CR15","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0002-9378(91)90075-3","volume":"165","author":"RT Gerhardt","year":"1991","unstructured":"Gerhardt RT, Perras JP, Sevin BU, Petru E, Ramos R, Guerra L, Averette HE (1991) Characterization of in vitro chemosensitivity of perioperative human ovarian malignancies by adenosine triphosphate assay. Am J Obstet Gynecol 165:245\u2013255","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"13_CR16","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1006\/gyno.2000.5728","volume":"77","author":"G Konecny","year":"2000","unstructured":"Konecny G, Crohns C, Pegram M, Felber M, Lude S, Kurbacher C, Cree IA, Hepp H, Untch M (2000) Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer. Gynecol Oncol 77(2):258\u201363","journal-title":"Gynecol Oncol"},{"key":"13_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199601043340101","volume":"334","author":"WP McGuire","year":"1996","unstructured":"McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. New Engl J Med 334:1\u20136","journal-title":"New Engl J Med"},{"key":"13_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1006\/gyno.1994.1085","volume":"53","author":"M Untch","year":"1994","unstructured":"Untch M, Sevin BU, Perras JP, Angioli R, Untch A, Hightower RD, Koechli O, Averette HE (1994) Evaluation of paclitaxel (Taxol), cisplatin, and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell viability assay. Gynecol Oncol 53:44\u201349","journal-title":"Gynecol Oncol"},{"key":"13_CR19","first-page":"1527","volume":"3","author":"CM Kurbacher","year":"1997","unstructured":"Kurbacher CM, Bruckner HW, Cree IA, Kurbacher JA, Wilhelm L, Poch G, Indefrei D, Mallmann P, Andreotti PE (1997) Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial. Clin Cancer Res 3:1527\u20131533","journal-title":"Clin Cancer Res"},{"key":"13_CR20","unstructured":"Kurbacher CM, Bruckner HW, Cree IA et al. (1999) A prospective clinical trial on individualized chemotherapy directed by a tumor chemosensitivity assay versus physicia\u0144s choice in patients with platinum-resistant ovarian adenocarcinoma."},{"key":"13_CR21","first-page":"242","volume":"19","author":"EM Hunter","year":"1993","unstructured":"Hunter EM, Sutherland LA, Cree IA et al. (1993) Heterogeneity of chemosensitivity in human breast carcinoma: use of an adenosine triphosphate (ATP) chemiluminescence assay. Eur J Surg Oncol 19:242\u2013249","journal-title":"Eur J Surg Oncol"},{"key":"13_CR22","first-page":"271","volume":"118","author":"CM Kurbacher","year":"1996","unstructured":"Kurbacher CM, Brenne U, Kurbacher JA, Mallmann P, Krebs D. (1996) Vergleich der zytostatischen Wirkung von Epirubicin und Mitoxantron auf native Mammakarzinomzellen mit Hilfe des ATP-Tumor-Chemosensitivit\u00e4ts-Assays. Zentbl Gyn\u00e4kol 118:271\u2013278","journal-title":"Zentbl Gyn\u00e4kol"},{"key":"13_CR23","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1097\/00001813-199608000-00002","volume":"7","author":"IA Cree","year":"1996","unstructured":"Cree IA, Kurbacher CM, Untch M, Sutherland LA, Hunter EM, Subedi AM, James EA, Dewar JA, Preece PE, Andreotti PE, Bruckner HW. (1996) Correlation of the clinical response to chemotherapy in breast cancer with ex vivo chemosensitivity. Anti-Cancer Drugs 7:630\u2013635","journal-title":"Anti-Cancer Drugs"},{"key":"13_CR24","first-page":"236","volume":"39","author":"CM Kurbacher","year":"1998","unstructured":"Kurbacher CM, Bruckner HW, Goor A et al. (1998) Influence of p53 and bcl-2 on the ex vivo chemosensitivity of clinical ovarian carcinomas. Proc Am Assoc Cancer 39:236","journal-title":"Proc Am Assoc Cancer"},{"key":"13_CR25","first-page":"R154","volume":"124","author":"M-M Jan\u00e1t","year":"1998","unstructured":"Jan\u00e1t M-M, Kurbacher CM, Goor A et al. (1998) Lack of correlation between p53\/bcl-2 expression and breast chemosensitivity ex vivo. J Cancer Res Clin Oncol 124:R154","journal-title":"J Cancer Res Clin Oncol"},{"key":"13_CR26","first-page":"5069","volume":"20","author":"DT Rein","year":"2000","unstructured":"Rein DT, Schondorf T, Breidenbach M, Janat MM, Weikelt A, Gohring UJ, Becker M, Mallmann P, Kurbacher CM (2000) Lack of correlation p53 expression, bcl-2 expression, apoptosis and ex vivo chemosensitivity in advanced human breast cancer. Anticancer Res 20 (6D):5069\u20135072","journal-title":"Anticancer Res"},{"key":"13_CR27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/BF02904701","volume":"4","author":"R Petty","year":"1998","unstructured":"Petty R, Evans A, Duncan I, Kurbacher C, Cree I (1998) Drug resistance in ovarian cancer \u2014 the role of p53. Path Oncol Res 4:97\u2013102","journal-title":"Path Oncol Res"},{"key":"13_CR28","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1056\/NEJM199405053301802","volume":"330","author":"HB Muss","year":"1994","unstructured":"Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koerner F, Cirrincione CT, Budman DR, Wood WC, Barcos M, et al. (1994) C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. New Engl J Med 330:1260\u20131266","journal-title":"New Engl J Med"},{"key":"13_CR29","first-page":"103","volume":"17","author":"M Untch","year":"1998","unstructured":"Untch M, Konecny G, Lebeau A et al. (1998) Dose-intensification (DI) of anthracycline in the adjuvant treatment of high risk breast cancer (HRBC) and c-erbB-2 overexpression. Proc ASCO 17:103a","journal-title":"Proc ASCO"},{"key":"13_CR30","unstructured":"Kurbacher CM, Brenne U, G\u00f6hring UJ et al. (1999) HER2 status of primary breast carcinomas and ex vivo chemosensitivity against anthracyclines and taxanes. 1st HER2 State-of-the-Art Conference, San Antonio Breast Cancer Meeting 12\/2000"},{"key":"13_CR31","unstructured":"Isola J, J\u00e4runen T, Tanner M et al. (1999) Topoisomerase-II\u03b1 aberrations may explain altered chemosensitivity of HER2-amplified breast cancers. 1st HER2 State-of-the-Art Conference, San Antonio Breast Cancer Meeting 12\/2000"},{"key":"13_CR32","unstructured":"Crohns C, Untch M, Konecny G (2001) Different Bisphosphonates have direct cytotoxic effects on three breast cancer lines and fresh breast cancer tumor tissue. 37th Annual Meeting ASCO 2001"},{"key":"13_CR33","unstructured":"Kurbacher CM (2000) DGGG 2000"},{"key":"13_CR34","unstructured":"Powles et al. Breast Cancer Research Treatment."}],"container-title":["Recent Results in Cancer Research","Chemosensitivity Testing in Oncology"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-19022-3_13.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,30]],"date-time":"2021-04-30T09:12:29Z","timestamp":1619773949000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-642-19022-3_13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003]]},"ISBN":["9783642624124","9783642190223"],"references-count":34,"URL":"https:\/\/doi.org\/10.1007\/978-3-642-19022-3_13","relation":{},"ISSN":["0080-0015"],"issn-type":[{"type":"print","value":"0080-0015"}],"subject":[],"published":{"date-parts":[[2003]]}}}